Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Politics

Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments

admin by admin
July 29, 2025
in Politics
0
Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Sarepta Therapeutics shares jumped over 36% in premarket trading on Tuesday after the company said it had received US Food and Drug Administration (FDA) approval to restart shipments of its flagship gene therapy Elevidys in the United States.

The move provides the biotech company with some much-needed breathing room after coming under pressure for months following deaths in the patient group, raising questions about the future of its lead revenue-generating Duchenne muscular dystrophy (DMD) product, Elevidys.

Shipments restart following FDA review

Sarepta announced on Monday that it would restart distribution of Elevidys to ambulatory patients in the United States, following the FDA’s recommendation to lift the voluntary shipping hold.

The action came after an official probe into the death of an 8-year-old child in Brazil, which found no relation to the therapy.

Shipments to patients who are unable to walk independently have been halted while regulators and the firm review safety data following the deaths of two teens in the United States earlier this year.

Financial outlook improves

Wall Street responded strongly to the news. Analysts said the ability to continue limited shipments revives Sarepta’s near-term financial risk mitigation plans as it has a payment to its partner, Arrowhead Pharmaceuticals (ARWR.O), and maintains access to debt facilities.

“The FDA’s recommendation and the resumption of commercial treatment in the US virtually eliminate the risk of Elevidys being formally withdrawn from the market,” Sami Corwin, an analyst at William Blair, said.

That ruling is a major win for Sarepta, which saw its shares fall over 80% since March, after the initial death linked to Elevidys was reported. Shares climbed 36% to $18.85 in early Tuesday trading.

Lingering market concerns

Despite the quick turnaround, analysts warned that the deaths’ reputational harm could harm the company’s business momentum.

Elevidys uptake may be limited soon due to patient and physician hesitation, even if access improves for eligible persons.

“It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term,” according to Corwin.

The drug, which was approved to treat DMD in walkable patients, faced growing uncertainty as Sarepta’s global operations were disrupted.

Partner Roche (ROG.S) had also delayed shipments to select areas outside the United States, raising concerns among investors about the drug’s long-term sustainability.

Path forward remains uncertain

While the FDA’s findings in the Brazil case provide some reassurance, Sarepta’s future route is still contingent on broader regulatory clarity and the results of ongoing safety reviews.

The company has not offered an update on when or whether shipments to non-ambulatory patients would resume.

For the time being, the restart of Elevidys shipments to a subset of patients is a key win for Sarepta, mitigating some of the most urgent market threats and stabilising its financial position.

However, with unanswered problems about perception and access, the company’s recovery remains a work in progress.

The post Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments appeared first on Invezz

Previous Post

Spotify stock drops 4% after Q2 miss and weak Q3 guidance

Next Post

Boeing trims losses and lifts output in strongest quarter since 2023 but shares fall

admin

admin

Next Post
Boeing trims losses and lifts output in strongest quarter since 2023 but shares fall

Boeing trims losses and lifts output in strongest quarter since 2023 but shares fall

Trending News

US stocks climb as Fed keeps rates steady, Dow Jones, S&P 500, Nasdaq Composite all gain

US stocks climb as Fed keeps rates steady, Dow Jones, S&P 500, Nasdaq Composite all gain

March 20, 2025
Will Europe do whatever it takes?

Will Europe do whatever it takes?

September 28, 2024
How consumers and business might be impacted by potentially sweeping tariffs

How consumers and business might be impacted by potentially sweeping tariffs

December 15, 2024
Subscribe to Insightful Word


    Recent News

    Estée Lauder shares fall on weak outlook and $100 mn tariff warning

    Estée Lauder shares fall on weak outlook and $100 mn tariff warning

    August 20, 2025
    Target shares fall 10% as new CEO named, Q2 earnings hit $25.21B

    Target shares fall 10% as new CEO named, Q2 earnings hit $25.21B

    August 20, 2025
    Target stock tanks 10% on Wednesday: here’s why analysts are cautious

    Target stock tanks 10% on Wednesday: here’s why analysts are cautious

    August 20, 2025
    US stocks mixed at open as investors await Fed minutes: Nasdaq down 0.3%

    US stocks mixed at open as investors await Fed minutes: Nasdaq down 0.3%

    August 20, 2025

    Recent News

    Estée Lauder shares fall on weak outlook and $100 mn tariff warning

    Estée Lauder shares fall on weak outlook and $100 mn tariff warning

    August 20, 2025
    Target shares fall 10% as new CEO named, Q2 earnings hit $25.21B

    Target shares fall 10% as new CEO named, Q2 earnings hit $25.21B

    August 20, 2025

    Latest News

    • Estée Lauder shares fall on weak outlook and $100 mn tariff warning
    • Target shares fall 10% as new CEO named, Q2 earnings hit $25.21B
    • Target stock tanks 10% on Wednesday: here’s why analysts are cautious

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.